Skip to main content
. Author manuscript; available in PMC: 2021 Sep 29.
Published in final edited form as: Nat Med. 2017 Feb 7;23(2):1–13. doi: 10.1038/nm.4269

Figure 2.

Figure 2

Therapeutically targeting α-synuclein toxicity. Various pathways have been manipulated to decrease α-synuclein toxicity, largely in mouse models of α-synuclein toxicity. These include (i) reducing α-synuclein synthesis with siRNAs, (ii) increasing α-synuclein degradation, (iii) reducing α-synuclein aggregation, (iv) blocking α-synuclein propagation and (v) active immunization of α-synuclein. Drug development to increase lysosomal activity via glucocerebrosidase (GCase) to accelerate α-synuclein degradation, as well as clinical trials using both passive and active immunization against α-synuclein, are currently under way.